Ann: Costs arising in response to Non-Binding Indicative Proposal, page-32

First 32 Last

Share
Profile

Follow
Dom2007

522 Posts.

68

17/11/21

15:34

Post #: 57645227
Share

Originally posted by Mr.Gold: ↑

sure you do... So are you talking Mergers and acquisition costs accumulated that never eventuated, or Mergers and acquisitions costs with the deal progressing... come on man... if you know it so well why don't you entertain us with a break down on how near $500,000 of shareholder money can be spent on something that never eventuated... lets be real hey..

leave you guys to it... I think the writing is on the wall here... 9spokes is not progressing as portrayed.. cash burn is high, revenue is low, forever loss making after near 10years... platform is average... Adrian getting a fat income and helping his mates out along the way it would seem... after all we know via the charts that insider info seems to leak easy here

I know of stupid game apps that were invented and profited in the tens of millions in under 2 years, you would think 9spokes would be cash flow positive by now after near 10 years with all the so called partnerships they have achieved... last CR was $10million.... burning through that in no time... Baldy was right, I stand corrected, I once believed that the $10million was the last CR needed for 9SP, he portrayed another would be needed within 2 years... I think he is 100% on point, more dilution for shareholders ... Adrian being a exbroker seems to know how to play the market.. he is making a some fat coin for himself in the mean time...

caution needed here for on lookers IMO...

Any way, Ive made my point... enough from me (thank god you say, lol) ... good luck shareholders... I think you will need it

Expand

Do you think Uber make profit? Do you know the value of Uber now?

9SP Price at posting: 1.3¢ Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

There are more pages in this discussion • 33 more messages in this thread...

First 32 Last

Add 9SP (ASX) to my watchlist

Ann: Costs arising in response to Non-Binding Indicative Proposal, page-32

Top Stories

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News